SIREN : 814422721
MEDIFON is a French company founded 10 years ago, specialized in the sector Activités des marchands de biens immobiliers. Based in AUBAGNE (13400), this company of category PME shows in 2024 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 580 161 € | 1 527 740 € | 1 422 949 € | 1 329 739 € | 1 298 389 € | 1 275 787 € | 1 261 468 € | 1 243 270 € | 1 295 703 € |
| Net income | 234 940 € | 195 946 € | 1 468 929 € | -263 234 € | -657 535 € | 210 024 € | 192 111 € | -654 689 € | -82 003 € |
| EBITDA | 403 415 € | 360 277 € | 277 391 € | -246 667 € | -701 398 € | -1 411 732 € | -198 560 € | -26 991 € | -358 258 € |
| Net margin | 14.9% | 12.8% | 103.2% | -19.8% | -50.6% | 16.5% | 15.2% | -52.7% | -6.3% |
In 2024, MEDIFON achieves revenue of 1.6 M€. Revenue is growing positively over 9 years (CAGR: +2.5%). Vs 2023: +3%. After deducting consumption (325 €), gross margin stands at 1.6 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 403 k€, representing 25.5% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 235 k€, i.e. 14.9% of revenue. This profit can be retained or distributed to shareholders.
1 580 161 €
1 579 836 €
403 415 €
290 777 €
234 940 €
25.5%
The debt ratio (= Financial debt / Equity x 100) stands at 104%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 45%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.9 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 22.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
103.655%
44.968%
21.996%
4.904
80.0%
In 2024, the debt ratio of MEDIFON (103.66) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of MEDIFON (45.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of MEDIFON (4.90) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 220.05. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 7.8x. Operating income very largely covers interest expenses: high safety margin.
220.051
7.825
In 2024, the liquidity ratio of MEDIFON (220.05) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of MEDIFON (7.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 3 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 86 days. Excellent situation: suppliers finance 83 days of the operating cycle (retail model). Overall, WCR represents 18 days of revenue, i.e. 80 k€ to permanently finance. Over 2016-2024, WCR increased by +201%, requiring additional financing.
79 609 €
3 j
86 j
0 j
18 j
Indicative estimate only : the number of comparable transactions in this sector is limited (22 transactions). This range of 970 639€ to 2 200 945€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 22 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDIFON with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des marchands de biens immobiliers
The revenue of MEDIFON in 2024 is 1.6 M€.
Yes, MEDIFON generated a net profit of 235 k€ in 2024.
The headquarters of MEDIFON is located in AUBAGNE (13400), in the department Bouches-du-Rhone.
The tax return of MEDIFON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDIFON operates in the sector Activités des marchands de biens immobiliers (NAF code 68.10Z). See the 'Sector positioning' section above to compare the company with its competitors.